AveXis To Present At Jefferies 2016 London Healthcare Conference

CHICAGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases , today announced that Sean Nolan, president and chief executive officer, will present at the Jefferies 2016 London Healthcare Conference at 11:20 a.m. GMT (6:00 a.m. EST), Wednesday, November 16, 2016.

A live, listen-only webcast of the presentation will be accessible on the Events and Presentations page within the Investors and Media section of the AveXis website at www.AveXis.com. A replay of the presentation will be available at the same location for 30 days following the conference.

About SMASMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births.

The most severe form of SMA is Type 1, a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. SMA Type 1 is the leading genetic cause of infant mortality.

About AVXS-101AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Type 1 and is designed to address the monogenic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN1 gene. AVXS-101 also targets motor neurons providing rapid onset of effect, and crosses the blood brain barrier allowing an IV dosing route and effective targeting of both central and systemic features.

About AveXis, Inc.AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company's initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.AveXis.com.

Media Inquiries:Lauren BarbieroW2O Group646-564-2156lbarbiero@w2ogroup.comInvestor Inquiries: Jim GoffAveXis, Inc.650-862-4134jgoff@avexis.com

Primary Logo

If you liked this article you might like

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion and Amgen Among Biotech Movers

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More